HomeClinical TopicsFDA halts Avandia trial enrollment

FDA halts Avandia trial enrollment

The U.S. Food and Drug Administration (FDA) notified GlaxoSmithKline that the post-marketing trial of Avandia (rosiglitazone) is on “partial clinical hold,” meaning no new patients can be enrolled until further notice by the FDA. Patients already enrolled can continue to participate. Read more here.


Please enter your comment!
Please enter your name here

Most Recent Content